Skip to content

Quantification of Metamorphopsia in Patients With Epiretinal Membranes

Quantification of Metamorphopsia Using the Alleye App Compared to the M-chart in Patients With Epiretinal Membranes a Pilot Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05138315
Enrollment
30
Registered
2021-11-30
Start date
2021-11-16
Completion date
2022-12-31
Last updated
2021-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epiretinal Membrane

Brief summary

Aim of this study is to examine metamorphopsia before and 3 months after vitrectomy with membrane peeling among patients with idiopathic epiretinal membranes. Therefore, the correlation between the Alleye App and the M-chart test before and after ERM surgery and the associations of OCT biomarkers to postsurgical changes in metamorphopsia scores will be examined.

Detailed description

Epiretinal membranes are common disorders leading to visual loss and metamorphopsia in later stages. In most cases they are idiopathic with no identifiable cause (iERM). ERM can be visualized with optical coherence tomography (OCT) and can cause metamorphopsia, usually diagnosed with the Amsler grid or metamorphopsia chart (M-chart), which have influence on vision. ERM are surgically treated by vitrectomy and membrane peeling, however, postoperative visual acuity and quality of vision are difficult to predict. Quality of vision is highly dependent on metamorphopsia which can be an overlooked symptom. Thus, detailed examinations using M-charts prior to surgery can help to quantify the degree of metamorphopsia and might predict the potential benefit of the surgery. Recently, home monitoring tests for metamorphopsia using handheld mobile devices are becoming increasingly important. The Alleye App is one of two m-health applications with FDA approval, that is already in use for monitoring the progression of metamorphopsia in other retinal diseases such as age-related macular degeneration (AMD). It has yet to be evaluated for ERM. Aim of this study is to examine the correlation between the Alleye App and the M-chart test before and after ERM surgery and the associations of OCT biomarkers to postsurgical changes in metamorphopsia scores.

Interventions

DEVICEMetamorphopsia quantification

Alleye App and M.chart examinations will be performed pre- and postsurgically.

Sponsors

Vienna Institute for Research in Ocular Surgery
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Idiopathic ERM * Sheduled surgery (vitrectomy with membrane peeling) * Age 18 and older * Written informed consent for participation in the study * Metamorphopsia detected by the Amsler grid * BCVA ≥ 0,1

Exclusion criteria

* Secondary ERM due to retinal tears, retinal detachment, retinal vascular diseases and uveitis * Other macular disorders including AMD * Previous intraocular surgery except for uncomplicated cataract surgery * Pregnancy (pregnancy test will be performed in women of reproductive age)

Design outcomes

Primary

MeasureTime frameDescription
Alleye App Score5 minutesThe Alleye App measures the degree of metamorphopsia, the range of the Alleye App Score: 0 to 100 points, with 100 being the best achievable result, while lower values are associated with increasing degree of metamorphopsia
M-chart Scores (horizontal and vertical)5 minutesThe M-charts measure the degree of horizontal and vertical metamorphopsia, the range of M-charts: 0 to 2.0, with higher values indicating a higher degree of metamorphopsia

Countries

Austria

Contacts

Primary ContactOliver Findl, Prof.
oliver.findl@oegk.at+43 1 91021 84611
Backup ContactChristoph Leisser, MD
christoph.leisser@oegk.at+43 1 91021 84611

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026